| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Elicio Therapeutics Inc. | ANG-3070 | Idiopathic Pulmonary Fibrosis | Phase 2 | Trial Discontinued | oral | Respiratory |
| Elicio Therapeutics Inc. | ELI-002 (AMPLIFY-201) | Solid Tumors | Phase 2 | Ongoing | Subcutaneous | Oncology |
| Elicio Therapeutics Inc. | ANG-3070 - (JUNIPER) | Primary proteinuric kidney diseases | Phase 2 | Trial Discontinued | oral | N/A |
| Elicio Therapeutics Inc. | ANG-3777 | Acute kidney injury (AKI) / Delayed Graft Function | Phase 3 | Trial Discontinued | Intravenous | N/A |
| Elicio Therapeutics Inc. | ELI-002 - (AMPLIFY-7P) | mKRAS-driven cancers | Phase 2 | Data Released | Subcutaneous | Oncology |
| Elicio Therapeutics Inc. | ANG-3777 - (GUARD) | Acute Kidney Injury associated with cardiac surgery | Phase 2 | Trial Discontinued | Intravenous | N/A |
| Eloxx Pharmaceuticals Inc. | ELX-02 | Cystinosis | Phase 2 | Intravenous | Genetic Disorder | |
| Eloxx Pharmaceuticals Inc. | ELX-02 | Alport syndrome | Phase 2 | Intravenous | Genetic Disorder |